Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2001

View Archived Issues

Allos Therapeutics reports year-end 2000 results, goals for 2001

Status of development programs at OSI

BioTime and Organon Teknika establish exclusive license agreement for Hextend

MicroHeart obtains exclusive license to angiogenic/antiinflammatory compound

Neurocrine reports additional positive clinical results with NBI-34060 for insomnia

Visicol to be copromoted by Procter & Gamble

EntreMed expands phase II 2ME2 program to include prostate cancer

AEterna enters two commercialization alliances for Neovastat in Europe

Adjunctive therapy with rufinamide safe, effective and devoid of significant PK interactions

Antihistaminic equivalence of cetirizine and levocetirizine demonstrated in healthy volunteers

Phase II trial establishes safety and optimal dose of PVAC psoriasis treatment

Potential of PPARgamma agonists in stroke demonstrated in rats using troglitazone

Neuroprotective Ca2+ channel blocker acts by attenuating ischemia-induced glutamate release

Idun presents inhibitors of ICE/ced-3 cysteine proteases

Selective human PPARdelta receptor agonists and their use in type 2 diabetes and related disorders

VLA-4 antagonists with oral activity emerge from Daiichi/Pharmacopeia collaboration

Cytokine inhibitors in the Merck pipeline

New Aventis compounds block Kv1.5 potassium channels

Janssen devotes significant resources to discovery of antiviral agents

Potential new antiulcer agent DBM-819 characterized in vitro and in vivo

Positive hemodynamic results reported in phase III trial of tezosentan

Cyclacel to evaluate lead CDK2 inhibitor in phase I

TMP-substituted phenazine B-4128: antimycobacterial activity and mechanism of action

Akzo Nobel receives offer from bioMerieux for diagnostics business

OP-1 Implant recommended for approval in Australia

Excellent antianaerobic activity demonstrated for BMS-284756

CytRx begins research project with potential treatment for spinal cord injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...